Fellow Shareholders, do yourself a favor and send the REGISTERED SIGNATURE REQUIRED letter that CP suggested before October 10
Sounds like there will be lots of letters being sent to Tustin, the SEC and Nasdaq. Hopefully everyone sends! : )
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!